Abiopharma

ANTERIS TECHNOLOGIES GLOBAL CORP. (AVR)

Symbol	AVR
Name	ANTERIS TECHNOLOGIES GLOBAL CORP.
Sector	HEALTH CARE
Region	North America
Industry	Industrial Specialties
Address	860 BLUE GENTIAN ROAD,SUITE 340, EAGAN, Minnesota, 55121, United States
Telephone	651-493-0606
Fax	—
Email	—
Website	https://anteristech.com/home.html
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0002011514
Description	Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis. Our lead product, the DurAVR® transcatheter heart valve ("THV") system, represents a unique product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Our DurAVR® THV System consists of a single-piece, biomimetic valve made with our proprietary ADAPT® tissue-enhancing technology and depoloyed with our ComASUR® balloon-expahndable delivery system. ADAPT® is our proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Additional info from NASDAQ: Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis. Our lead product, the DurAVR® transcatheter heart valve ("THV") system, represents a unique product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Our DurAVR® THV System consists of a single-piece, biomimetic valve made with our proprietary ADAPT® tissue-enhancing technology and depoloyed with our ComASUR® balloon-expahndable delivery system. ADAPT® is our proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.

2026-06-10 01:46

Moss Gregory S. 🟡 adjusted position in 0 shares (1 derivative) of Anteris Technologies Global Corp. (AVR) Transaction Date: Jun 07, 2026 | Filing ID: 024701

2026-06-10 01:41

Roberts David B 🟡 adjusted position in 0 shares (1 derivative) of Anteris Technologies Global Corp. (AVR) Transaction Date: Jun 07, 2026 | Filing ID: 024699

2026-06-10 00:56

McDonnell Matthew 🟡 adjusted position in 39.6K shares (2 derivative) of Anteris Technologies Global Corp. (AVR) at $9.83 ($1.2M) Transaction Date: Jun 05, 2026 | Filing ID: 024693

2026-06-04 22:01

Knight Susan Elizabeth 🟢 acquired 11.0K shares of Anteris Technologies Global Corp. (AVR) at $9.29 Transaction Date: Jun 02, 2026 | Filing ID: 024019

2026-05-26 17:46

New Form 424B3 - Anteris Technologies Global Corp. Filed: 2026-05-26 AccNo: 0001140361-26-022862 Size: 344 KB

2026-05-22 21:15

(99% Neutral) ANTERIS TECHNOLOGIES GLOBAL CORP. (AVR) Announces Business Combination

2026-05-22 18:15

New Form 424B5 - Anteris Technologies Global Corp. Filed: 2026-05-22 AccNo: 0001140361-26-022632 Size: 650 KB

2026-05-21 19:08

New Form 3 - Anteris Technologies Global Corp. Filed: 2026-05-21 AccNo: 0001140361-26-022477 Size: 3 KB

2026-05-15 17:44

New Form SCHEDULE 13G/A - Anteris Technologies Global Corp. Filed: 2026-05-15 AccNo: 0001104659-26-062713 Size: 11 KB

2026-05-04 17:15

New Form SCHEDULE 13G/A - Anteris Technologies Global Corp. Filed: 2026-05-04 AccNo: 0001214659-26-005497 Size: 8 KB

No clinical trials found for this company.

No clinical products found for this company.